Get started Log in

1952 — Everest Medicines Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapSucker Stock

Market Cap
HK$11.47bn
Enterprise Value
HK$11.42bn
Revenue
CNY1.71bn

Brief: Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves ETRASIMOD For Adults With Moderately To Severely Active Ulcerative Colitis
16/10/2023 24:53
Brief: Everest Medicines Ltd Entered Into A Collaboration And License Agreement With Kezar Life Sciences
21/09/2023 01:11
Brief: Kezar Life Sciences And Everest Medicines Enter Into An Agreement To Develop And Commercialize Zetomipzomib For Lupus Nephritis And Other Potential Indications In Greater China, South Korea And Southeast Asia
20/09/2023 23:30
Brief: Everest Medicines Says Partner Calliditas Therapeutics Receives FDA Priority Review For Full Approval Of Nefecon
21/08/2023 01:36
Brief: Everest Medicines' Partner Venatorx Receives FDA Acceptance, Priority Review Of NDA For Cefepime-Taniborbactam
15/08/2023 13:14
Brief: Everest Medicines Announces New Drug Application Acceptance By Singapore HSA For Nefecon For The Treatment Of Primary IgA Nephropathy
06/04/2023 24:31
Brief: Everest Medicines Says Xiaofan Zhang Resigned As Executive Director
31/03/2023 10:55
Brief: Everest Medicines Says FY Loss Attributable RMB247.3 Mln
31/03/2023 24:00
Brief: Everest Medicines Announces Signing Of MoU For Strategic Cooperation With Guangdong Academy Of Medical Sciences In Renal Diseases
23/03/2023 10:02
Brief: Everest Medicines Says NMPA Of China Approved New Drug Application For Xeravatm
17/03/2023 01:11
Brief: Everest Medicines Announces Approval Of Xerava In China
16/03/2023 12:40
HK-listed Everest Medicines jumps after saying it has minimal exposure to SVB
13/03/2023 05:10
Brief: Everest Medicines Says Has Immaterial Amount Of Cash On Deposit At Silicon Valley Bank
13/03/2023 01:24
Brief: Everest Medicines Announces Data From Phase I Study Of Ever206
17/01/2023 23:31
Brief: Everest Medicines Announces China NMPA Recommends Priority Review For Nefecon For Primary IGA Nephropathy
30/12/2022 24:03
Brief: Everest Medicines Announces Partner Providence Reports Positive Top-Line Data From Phase 2 Primary Immunization Trial For Mrna Covid-19 Vaccine Candidate In Adults
19/10/2022 13:17
Brief: Everest Medicines Says Yongqing Luo Appointed As Executive Director and CEO
19/09/2022 02:28
Brief: Everest Medicines Says Kerry Levan Blanchard Resigned As Chief Executive Officer
26/08/2022 02:15
HY Net Loss Rmb668.0 Million Versus Loss Of Rmb383.1 Million
24/08/2022 15:32
Brief: Everest Medicines Says Units Entered Agreement With Immunomedics
16/08/2022 02:28